免疫检查点抑制剂联合疗法在晚期非小细胞肺癌中的疗效研究进展
Research Progress on the Efficacy of Immune Checkpoint Inhibitor Combination Therapy in Advanced Non-Small Cell Lung Cancer
DOI: 10.12677/hjbm.2025.152030, PDF,    科研立项经费支持
作者: 马普艳, 申艳梅：大理大学药学院，云南 大理；李春华：昆明医科大学药学院，云南 昆明；罗铁成, 闵秋霞, 曹 玮*：云南省第一人民医院/昆明理工大学附属医院药学部，云南 昆明
关键词: 免疫检查点抑制剂；非小细胞肺癌；免疫治疗；Immune Checkpoint Inhibitors； Non-Small Cell Lung Cancer； Immunotherapy
摘要: 晚期非小细胞肺癌临床治疗选择有限且获益率低。如何延长生存期、提高生活质量及控制症状成为了当前研究的热点。免疫检查点抑制剂是治疗晚期非小细胞肺癌的重要手段，但患者临床治疗的应答率低。近年来，免疫检查点抑制剂联合疗法成为了抑制肿瘤发展的新策略。深入探究药物联用以及新兴免疫疗法的联合应用，或将成为提高肿瘤免疫疗效的关键策略之一，且对提高免疫检查点抑制剂临床治疗有效率及指导临床合理用药都具有重要的理论和实践价值。因此，本综述将总结常见免疫检查点抑制剂在晚期非小细胞肺癌中的疗效研究进展。
Abstract: The clinical treatment options for advanced non-small cell lung cancer are limited and the success rate is low. The question of how to prolong survival, improve quality of life and control symptoms is the focus of current research. Immune checkpoint inhibitors (ICIs) are important for the treatment of advanced non-small cell lung cancer (NSCLC), but the response rate to clinical treatment is low. In recent years, combination therapy with ICIs has emerged as a new strategy to inhibit tumor development. The in-depth research of drug combinations and the combination of immunotherapies will become one of the key strategies to improve the efficacy of tumor immunity, and has important theoretical and practical value for improving the clinical efficacy of ICIs and for the rational use of clinical drugs. Therefore, this review summarizes the research progress of current ICIs in NSCLC.
文章引用：马普艳, 李春华, 申艳梅, 罗铁成, 闵秋霞, 曹玮. 免疫检查点抑制剂联合疗法在晚期非小细胞肺癌中的疗效研究进展[J]. 生物医学, 2025, 15(2): 265-272. https://doi.org/10.12677/hjbm.2025.152030

参考文献

[1] Leiter, A., Veluswamy, R.R. and Wisnivesky, J.P. (2023) The Global Burden of Lung Cancer: Current Status and Future Trends. Nature Reviews Clinical Oncology, 20, 624-639. [Google Scholar] [CrossRef] [PubMed]
[2] Raskova Kafkova, L., Mierzwicka, J.M., Chakraborty, P., Jakubec, P., Fischer, O., Skarda, J., et al. (2024) NSCLC: From Tumorigenesis, Immune Checkpoint Misuse to Current and Future Targeted Therapy. Frontiers in Immunology, 15, Article 1342086. [Google Scholar] [CrossRef] [PubMed]
[3] Passaro, A., Jänne, P.A., Mok, T. and Peters, S. (2021) Overcoming Therapy Resistance in EGFR-Mutant Lung Cancer. Nature Cancer, 2, 377-391. [Google Scholar] [CrossRef] [PubMed]
[4] Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Dal Bello, M.G., et al. (2019) Microtubule-Targeting Agents in the Treatment of Non-Small Cell Lung Cancer: Insights on New Combination Strategies and Investigational Compounds. Expert Opinion on Investigational Drugs, 28, 513-523. [Google Scholar] [CrossRef] [PubMed]
[5] Guo, X., Chen, S., Wang, X. and Liu, X. (2023) Immune-Related Pulmonary Toxicities of Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Diagnosis, Mechanism, and Treatment Strategies. Frontiers in Immunology, 14, Article 1138483. [Google Scholar] [CrossRef] [PubMed]
[6] Ji, M., Liu, Y., Li, Q., Li, X., Zhao, W., Zhang, H., et al. (2015) PD-1/PD-L1 Pathway in Non-Small-Cell Lung Cancer and Its Relation with EGFR Mutation. Journal of Translational Medicine, 13, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
[7] Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[8] Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. Clinics in Chest Medicine, 41, 237-247. [Google Scholar] [CrossRef] [PubMed]
[9] Nagel, T., Kalden, J.R. and Manger, B. (1998) Regulation der T-Zell-Aktivierung über CD28 und CTLA-4. Medizinische Klinik, 93, 592-597. [Google Scholar] [CrossRef] [PubMed]
[10] Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science, 271, 1734-1736. [Google Scholar] [CrossRef] [PubMed]
[11] Yang, J.C., Han, B., De La Mora Jiménez, E., Lee, J., Koralewski, P., Karadurmus, N., et al. (2024) Pembrolizumab with or without Lenvatinib for First-Line Metastatic NSCLC with Programmed Cell Death-Ligand 1 Tumor Proportion Score of at Least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. Journal of Thoracic Oncology, 19, 941-953. [Google Scholar] [CrossRef] [PubMed]
[12] Herbst, R.S., Garon, E.B., Kim, D., Cho, B.C., Perez-Gracia, J.L., Han, J., et al. (2020) Long-Term Outcomes and Retreatment among Patients with Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 38, 1580-1590. [Google Scholar] [CrossRef] [PubMed]
[13] Nishio, M., Takahashi, T., Yoshioka, H., Nakagawa, K., Fukuhara, T., Yamada, K., et al. (2019) Keynote‐025: Phase 1b Study of Pembrolizumab in Japanese Patients with Previously Treated Programmed Death Ligand 1-Positive Advanced Non-Small‐Cell Lung Cancer. Cancer Science, 110, 1012-1020. [Google Scholar] [CrossRef] [PubMed]
[14] Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., et al. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. [Google Scholar] [CrossRef] [PubMed]
[15] Garon, E.B., Aerts, J., Kim, J.S., Muehlenbein, C.E., Peterson, P., Rizzo, M.T., et al. (2021) Safety of Pemetrexed Plus Platinum in Combination with Pembrolizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Keynote-189. Lung Cancer, 155, 53-60. [Google Scholar] [CrossRef] [PubMed]
[16] Xing, P., Wang, M., Zhao, J., Zhong, W., Chi, Y., Xu, Z., et al. (2021) Study Protocol: A Single‐Arm, Multicenter, Phase II Trial of Camrelizumab Plus Apatinib for Advanced Nonsquamous NSCLC Previously Treated with First‐Line Immunotherapy. Thoracic Cancer, 12, 2825-2828. [Google Scholar] [CrossRef] [PubMed]
[17] Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S., Carcereny Costa, E., et al. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. [Google Scholar] [CrossRef] [PubMed]
[18] Kelley, R.K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y., et al. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001. [Google Scholar] [CrossRef] [PubMed]
[19] Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., et al. (2024) Four-Year Overall Survival Update from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Annals of Oncology, 35, 448-457. [Google Scholar] [CrossRef] [PubMed]
[20] Lotze, M.T., Olejniczak, S.H. and Skokos, D. (2024) CD28 Co-Stimulation: Novel Insights and Applications in Cancer Immunotherapy. Nature Reviews Immunology, 24, 878-895. [Google Scholar] [CrossRef] [PubMed]
[21] Kamphorst, A.O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D.L., et al. (2017) Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent. Science, 355, 1423-1427. [Google Scholar] [CrossRef] [PubMed]
[22] Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., et al. (2024) Immune Checkpoint Inhibitors: Breakthroughs in Cancer Treatment. Cancer Biology & Medicin. [Google Scholar] [CrossRef] [PubMed]
[23] Li, J., Huang, J., Jiang, Z., Li, R., Sun, A., Lai-Han Leung, E., et al. (2019) Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integrative Cancer Therapies, 18. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, W., Li, S., Li, C., Li, T. and Huang, Y. (2022) Remodeling Tumor Microenvironment with Natural Products to Overcome Drug Resistance. Frontiers in Immunology, 13, Article 1051998. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. [Google Scholar] [CrossRef] [PubMed]
[26] Huang, M., Jiang, X., Wang, B., Sun, Y. and Lu, J. (2021) Combination Therapy with PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer: Strategies and Mechanisms. Pharmacology & Therapeutics, 219, Article ID: 107694. [Google Scholar] [CrossRef] [PubMed]
[27] Butterfield, L.H. and Najjar, Y.G. (2023) Immunotherapy Combination Approaches: Mechanisms, Biomarkers and Clinical Observations. Nature Reviews Immunology, 24, 399-416. [Google Scholar] [CrossRef] [PubMed]
[28] Sholl, L.M. (2022) Biomarkers of Response to Checkpoint Inhibitors Beyond PD-L1 in Lung Cancer. Modern Pathology, 35, 66-74. [Google Scholar] [CrossRef] [PubMed]
[29] Lahiri, A., Maji, A., Potdar, P.D., Singh, N., Parikh, P., Bisht, B., et al. (2023) Lung Cancer Immunotherapy: Progress, Pitfalls, and Promises. Molecular Cancer, 22, Article No. 40. [Google Scholar] [CrossRef] [PubMed]

为你推荐